ArticleUltrasonics sonochemistry2026
HIFU-triggered burst release of gallic acid from gelatin/polyvinyl pyrrolidone hydrogel network crosslinked with magnesium gallate MOF.
Article in Ultrasonics sonochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we report the high-intensity focused ultrasound-triggered burst release of gallic acid from a gelatin-polyvinyl pyrrolidone (PVP) based hydrogel crosslinked with magnesium gallate (Mg-Gal) microparticles. Hydrogel was fabricated with 5% gelatin and 5% PVP as polymeric components crosslinked with 0.5% of Mg-Gal microparticles as crosslinker. Following physico-chemical characterization of the hydrogel, gallic acid release pattern was studied at different pH and temperature. In vitro biocompatibility & anti-cancer potential of microparticles and hydrogels were established. Further, high-intensity focused ultrasound (HIFU) induced drug release and enhanced bioactivity were also demonstrated. Fabricated hydrogels were characterized to show strong crosslinking network reinforced by ionic interactions. Mechanical and hydration properties correlated with release kinetics of gallic acid signifying the pH & temperature responsiveness of the hydrogel. PG-Mg-Gal showed excellent biocompatibility with dermal fibroblast (<10%) and inhibited the proliferation & migration of 4T1 cells. HIFU triggered the rapid release of gallic acid from PG-Mg-Gal, where the release rate was consistent for 30 min (30%) and up to 60% release was achieved at 90 mins. The drug release process showed consistently significant release rate compared to the untreated control. Enhanced bioactivity (20%; > 5 times of untreated hydrogel) of PG-Mg-Gal followed by burst release of gallic acid through HIFU treatment was demonstrated after 4 hrs using Live/Dead cells staining. In conclusion, HIFU-triggered delivery of gallic acid from PG-Mg-Gal showed great potential as a biocompatible and rapid delivery system which enhances the cytotoxic potential of Mg-Gal formulation through delivery at the targeted site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.